Actively Recruiting

Phase 1
Phase 2
Age: 18Years +
All Genders
NCT06911827

A Study of QLP2117 in Combination With QL2107 in Advanced Solid Tumor Patients

Led by Qilu Pharmaceutical Co., Ltd. · Updated on 2026-04-07

149

Participants Needed

1

Research Sites

186 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The goal of this clinical trial is to evaluate the safety and efficacy of QLP2117 in combination with QL2107 in Advanced Solid Tumor Patients.

CONDITIONS

Official Title

A Study of QLP2117 in Combination With QL2107 in Advanced Solid Tumor Patients

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Histological or cytological confirmation of recurrent or refractory advanced solid tumors, progressed on or intolerable for standard therapy, or no available standard therapy
  • At least one measurable disease per RECIST v1.1 for expansion cohorts (phase Iba dose escalation requires at least one assessable lesion)
  • Eastern Cooperative Oncology Group Performance Status of 0 or 1
  • Agree to provide archived tumor tissue samples of primary or metastatic lesions
  • Adequate organ function as described in the protocol
Not Eligible

You will not qualify if you...

  • Women who are pregnant or breastfeeding
  • Positive for HBsAg/HBcAb with HBV-DNA >1000 copy/mL or positive for HCV-Ab with viral replication
  • Currently participating in another study and receiving study medication within 4 weeks prior to the first dose
  • Active autoimmune disease requiring systemic treatment in the past 2 years
  • Active infection requiring systemic therapy
  • Received a live vaccine within 30 days before planned start of study treatment
  • Known history or evidence of interstitial lung disease

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Sun Yat-sen University Cancer Center

Guangzhou, Guangdong, China

Actively Recruiting

Loading map...

Research Team

R

Ruihua Xu, PhD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

A Study of QLP2117 in Combination With QL2107 in Advanced Solid Tumor Patients | DecenTrialz